Study of the Biological and Physical Manifestations of Spontaneous Uric Acid Kidney Stone Disease (IUAN)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by University of Texas Southwestern Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Takeda Pharmaceuticals North America, Inc.
Information provided by (Responsible Party):
Khashayar Sakhaee, University of Texas Southwestern Medical Center Identifier:
First received: May 15, 2009
Last updated: February 4, 2015
Last verified: February 2015

This study has two aims:

Aim 1: To determine the presence of accumulation of fat within cells and the functional consequences of this in the kidney by correlating kidney fat content with urine test results.

Aim 2: The investigators will evaluate the effect of thiazolidinedione (pioglitazone) on excess fatty acid accumulation in kidney tissue and its correlation with uric acid stone formation in subjects with uric acid stones.

Condition Intervention
Uric Acid Kidney Stone Disease
Drug: Pioglitazone
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: Pathophysiology of Uric Acid Nephrolithiasis

Resource links provided by NLM:

Further study details as provided by University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • Reversal of renal lipotoxicity will occur with pioglitazone. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: May 2009
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: April 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pioglitazone Drug: Pioglitazone
30 mg orally daily for 6 months
Other Name: Thiazolidinedione
Placebo Comparator: Placebo Drug: Placebo
Placebo taken orally once a day for 6 months.


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with uric acid kidney stone disease
  • Age > 21 years

Exclusion Criteria:

  • Body weight> 350 lb
  • Chronic alcohol use
  • Chronic liver disease
  • Chronic renal disease
  • Anemia
  • Contraindication to pioglitazone use:

    • history of congestive heart failure NYHA class III or IV
    • significant pedal edema
    • liver failure
    • not willing to practice an effective contraception for the duration of the study
  • Thiazolidinedione use in the preceding 18 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00904046

Contact: Ann Heard-Sakhaee, RN 214-648-4893
Contact: Marsha Roberts, RN 214-648-0399

United States, Texas
UT Southwestern Medical Center - Center for Mineral Metabolism Recruiting
Dallas, Texas, United States, 75390-8885
Sponsors and Collaborators
University of Texas Southwestern Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Takeda Pharmaceuticals North America, Inc.
  More Information

Additional Information:
No publications provided

Responsible Party: Khashayar Sakhaee, Professor of Internal Medicine, University of Texas Southwestern Medical Center Identifier: NCT00904046     History of Changes
Other Study ID Numbers: 1R01DK081423
Study First Received: May 15, 2009
Last Updated: February 4, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by University of Texas Southwestern Medical Center:
Uric acid

Additional relevant MeSH terms:
Kidney Calculi
Kidney Diseases
Pathological Conditions, Anatomical
Urinary Calculi
Urologic Diseases
Uric Acid
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents processed this record on November 24, 2015